Indications
Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
Composition
- Active substance
- asparaginase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Spectrila
- Active substance
- asparaginase
- ATC code
- L01XX02
- Therapeutic area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Marketing authorisation holder
- Medac Gesellschaft fuer klinische Spezialpraeparate mbH
- Status